Marcum Wealth LLC Trims Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Marcum Wealth LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 19.9% in the 4th quarter, HoldingsChannel reports. The firm owned 5,971 shares of the company’s stock after selling 1,486 shares during the quarter. Marcum Wealth LLC’s holdings in AstraZeneca were worth $391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in AZN. McClarren Financial Advisors Inc. raised its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of AstraZeneca during the third quarter worth $28,000. Groupama Asset Managment raised its holdings in shares of AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after purchasing an additional 101,225 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in AstraZeneca in the third quarter valued at $45,000. Finally, Versant Capital Management Inc increased its holdings in AstraZeneca by 2,618.5% in the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after buying an additional 707 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Down 0.5 %

AZN stock opened at $65.37 on Wednesday. The stock has a market capitalization of $202.69 billion, a P/E ratio of 31.28, a P/E/G ratio of 1.19 and a beta of 0.46. The firm has a 50-day simple moving average of $65.98 and a 200-day simple moving average of $74.69. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.87 earnings per share. Equities analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.